Johnson & Johnson (NYSE:JNJ) Shares Sold by Arthur M. Cohen & Associates LLC
Johnson & Johnson (NYSE:JNJ) Shares Sold by Arthur M. Cohen & Associates LLC
Arthur M. Cohen & Associates LLC decreased its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 8.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 15,663 shares of the company's stock after selling 1,401 shares during the quarter. Johnson & Johnson comprises about 0.8% of Arthur M. Cohen & Associates LLC's holdings, making the stock its 25th largest position. Arthur M. Cohen & Associates LLC's holdings in Johnson & Johnson were worth $2,767,000 at the end of the most recent reporting period.
亞瑟 ·M· 科恩 & 聯營有限責任公司下降了其在約翰遜地位 & 約翰遜 (紐約證券交易所:JNJ-獲得評級) 由 8.2% 在第四季度, 根據其最近的文件與證券交易委員會.本季度出售 1,401 股後，該基金擁有該公司股票的 15,663 股。約翰遜包括約 0.8% 亞瑟·科恩 & 聯營有限責任公司的控股, 使得股票的第 25 大位置.阿瑟·科恩 & 聯營有限責任公司在約翰遜的控股價值 $2,767,000 在最近的報告期結束.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in shares of Johnson & Johnson by 1.2% in the third quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company's stock valued at $40,078,885,000 after purchasing an additional 2,815,655 shares during the period. State Street Corp grew its holdings in Johnson & Johnson by 0.6% in the 3rd quarter. State Street Corp now owns 141,886,311 shares of the company's stock valued at $23,178,548,000 after buying an additional 803,013 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Johnson & Johnson by 3.3% during the 3rd quarter. Price T Rowe Associates Inc. MD now owns 25,428,626 shares of the company's stock valued at $4,154,022,000 after acquiring an additional 805,831 shares during the last quarter. Legal & General Group Plc lifted its holdings in shares of Johnson & Johnson by 2.3% during the 2nd quarter. Legal & General Group Plc now owns 18,839,914 shares of the company's stock worth $3,344,295,000 after acquiring an additional 421,779 shares during the period. Finally, FMR LLC boosted its position in shares of Johnson & Johnson by 20.8% in the second quarter. FMR LLC now owns 18,725,049 shares of the company's stock worth $3,323,883,000 after acquiring an additional 3,229,032 shares during the last quarter. 67.94% of the stock is currently owned by hedge funds and other institutional investors.
其他機構投資者和對沖基金最近也增加或減少了他們在公司的股份。領航集團股份有限公司在第三季度增長了 1.2％ 的強生公司股份地位。領航集團股份有限公司在期內額外購買 2,815,655 股股份後，擁有該公司股票價值 40,078,885,000 美元的 245,340,875 股股份。國街公司在第三季度增長了其在約翰遜的控股 0.6%.在期內另外購買 803,013 股股份後，州街公司現在擁有該公司股票的 141,886,311 股股份，價值為 23,178,548,000 美元。價格牛逼羅聯營公司 MD 在第三季度增加了其在約翰遜的股份的股份 3.3％。T 羅威聯營股份有限公司現在擁有該公司股票的 25,428,626 股價值在上個季度額外收購 805,831 股股份後，價值為 4,154,022,000 美元。法律與通用集團有限公司在第二季度取消了 2.3％ 在約翰遜的股份的持有量。法律與通用集團有限公司現在擁有該公司股票的 18,839,914 股價值 3,344,295,000 美元後，在此期間額外收購了 421,779 股。最後，FMR 有限責任公司在第二季度將其在約翰遜的股份中的地位提高了 20.8％。FMR 有限責任公司現在擁有該公司股票的 18,725,049 股，價值 3,323,883,000 美元，在上一季度獲得了 3,229,032 股。67.94％ 的股票目前由對沖基金和其他機構投資者擁有。
Analysts Set New Price Targets
分析師設定新的價格目標
A number of equities analysts have weighed in on the stock. Atlantic Securities increased their price target on shares of Johnson & Johnson from $160.00 to $168.00 and gave the stock a "neutral" rating in a research note on Wednesday, January 25th. Guggenheim started coverage on Johnson & Johnson in a research report on Tuesday, February 28th. They issued a "neutral" rating and a $161.00 target price on the stock. Morgan Stanley upped their price target on Johnson & Johnson from $176.00 to $180.00 and gave the stock an "equal weight" rating in a research note on Wednesday, January 25th. SVB Leerink reduced their price objective on Johnson & Johnson from $194.00 to $186.00 and set an "outperform" rating on the stock in a research note on Friday, January 20th. Finally, StockNews.com started coverage on shares of Johnson & Johnson in a research report on Thursday, March 16th. They set a "strong-buy" rating for the company. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $174.73.
一些股票分析師對股票進行了權衡。大西洋證券將強生公司股票的價格目標從 160.00 美元提高到 168.00 美元，並在 1 月 25 日（週三）的一份研究報告中給予該股「中性」評級。古根海姆開始覆蓋約翰遜 & 約翰遜週二的研究報告, 2 月 28 日.他們對股票發出了「中性」評級和 161.00 美元的目標價。摩根士丹利將約翰遜的價格目標從 176.00 美元提高到 180.00 美元，並在 1 月 25 日（週三）的研究報告中給予該股票「同等重量」評級。SVB Leerink 將其對約翰遜的價格目標從 194.00 美元降低至 186.00 美元，並在 1 月 20 日（星期五）的研究報告中設定了股票的「跑贏大市」評級。最後，Stocknews.com 在 3 月 16 日（星期四）的一份研究報告中開始對約翰遜的股票報導。他們為公司設定了「強買」評級。七位分析師對該股票進行了保持評級，其中六名分析師分配了買入評級，其中一名分析師對該公司的股票發出了強勁的買入評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為「中等買入」，平均目標價為 174.73 美元。
Johnson & Johnson Trading Up 1.0 %
約翰遜交易上升 1.0%
JNJ opened at $152.65 on Friday. The firm's 50 day moving average is $159.76 and its 200-day moving average is $167.55. Johnson & Johnson has a 52-week low of $150.11 and a 52-week high of $186.69. The company has a quick ratio of 0.77, a current ratio of 0.99 and a debt-to-equity ratio of 0.35. The firm has a market capitalization of $397.54 billion, a P/E ratio of 22.65, a P/E/G ratio of 2.60 and a beta of 0.54.
日本新澤西州上週五以 152.65 美元開業。該公司的 50 日移動平均線為 159.76 美元，其 200 天移動平均線為 167.55 美元。強生公司擁有 52 周低點 150.11 美元和 52 周高點 186.69 美元。該公司的快速比率為 0.77，流動比率為 0.99，債務與權益比率為 0.35。該公司的市值為 397.54 億美元，市盈率為 22.65，2.60 的市盈/克比率為 2.60，貝塔值為 0.54。
Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.22 by $0.13. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. The firm had revenue of $23.71 billion for the quarter, compared to the consensus estimate of $23.90 billion. During the same quarter in the previous year, the firm posted $2.13 EPS. The firm's quarterly revenue was down 4.4% on a year-over-year basis. Analysts expect that Johnson & Johnson will post 10.5 EPS for the current fiscal year.
強生公司（紐約證交所代碼：JNJ-獲取評級）最後一次公佈其季度盈利業績，星期二，1 月 24 日。該公司報告了該季度的每股盈利 2.35 美元，超過了 2.22 美元的共識估計高出 0.13 美元。強生的淨利潤率為 18.90％，股本回報率為 35.76％。該公司本季度的收入為 237.1 億美元，而共識估計為 233.9 億美元。在去年同一季度，該公司每股盈利 2.13 美元。該公司的季度收入較去年同期下降了 4.4%。分析師預計，約翰遜將在當前財政年度發布 10.5 每股盈利。
Johnson & Johnson Announces Dividend
強生宣佈股息
The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st were issued a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a yield of 2.96%. The ex-dividend date was Friday, February 17th. Johnson & Johnson's dividend payout ratio is currently 67.06%.
該公司最近還宣布了季度股息，該股息於 3 月 7 日（星期二）支付。投資者於 2 月 21 日（週二）發行了 1.13 美元的股息。這代表按年化基礎計算的股息為 4.52 美元，收益率為 2.96％。除息日期為 2 月 17 日星期五。強生的股息支付比率目前為 67.06%。
Insider Buying and Selling at Johnson & Johnson
約翰遜內幕購買和銷售
In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the company's stock in a transaction that occurred on Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the transaction, the insider now directly owns 9,215 shares of the company's stock, valued at approximately $1,425,191.90. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.35% of the stock is owned by insiders.
在其他約翰遜新聞中，內幕詹姆斯·斯旺森在 3 月 6 日（週一）發生的交易中出售了該公司股票的 1,062 股。該股票以 154.66 美元的平均價格出售，總價值為 164,248.92 美元。交易後，內幕人士現直接擁有該公司股票的 9,215 股股份，價值約為 1,425,191.90 美元。銷售在與 SEC 的文件中披露，該文件可通過以下方式訪問 證券交易所網站。0.35％ 的股票由內部人士擁有。
Johnson & Johnson Company Profile
強生公司簡介
(Get Rating)
(取得評分)
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women's Health and Wound Care markets.
Johnson & Johnson 是一家控股公司，從事醫療保健領域產品的研發、製造和銷售。它通過以下部分運作：消費者健康，藥品和醫療科技。消費者健康部門包括專注於皮膚健康/美容中使用的個人保健產品，非處方藥，嬰兒護理，口腔護理，婦女健康和傷口護理市場。
Featured Articles
特色文章
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- MarketBeat Week in Review – 3/20 – 3/24
- Dividend King Genuine Parts Company Upgraded On Profit Guidance
- The Bottom Is In For Accenture
- 11 Best Consumer Discretionary Stocks of 2023
- 5 Best Dividend Capture Stocks
- 獲取有關強生（JNJ）的研究報告的免費副本
- 市場節拍週的回顧 — 3 月 20 日 — 3/24
- 股息王原廠配件公司升級的利潤指導
- 底部是在埃森哲
- 11 股 2023 年最佳非必要消費品股票
- 5 個最佳股息捕捉股票
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
接收約翰遜日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Johnson 和相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。